Clinical trials: Oral Anticancer Drugs
Breast Cancer, ALL
Collaborative Network to Take Responsibility for Oral Anticancer Therapy
This study aims to develop, implement and evaluate a care pathway for patients with cancer who are treated with oral anticancer drugs (OACD).
- Conditions
- Breast Cancer, ALL, Lung Cancer, Melanoma
- Trial name
- CONTACT (NCT02861209)
- Testing
- Implementation of a care pathway
- Where
- 4 sites in Belgium
- Volunteers
- 228 people
- Sponsor
- KU Leuven
Cancer, Oral Anticancer Drugs
ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE
As the proportion of oral anticancer treatments is continuously increasing, adherence appears as a major issue for patients' outcomes.
- Trial name
- ADOPT-PRESTAGE (NCT03296150)
- Testing
- PRESTAGE
- Where
- 9 sites in France
- Volunteers
- 139 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
- Trial name
- NCT05548127
- Testing
- ARV-471, Abemaciclib
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 37 people
- Sponsor
- Pfizer
Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care…
- Conditions
- Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Chronic Conditions
- Trial name
- NCT04595851
- Testing
- Patient Reported Outcome Measure (PROM), Comprehensive Medication Review (CMR), Communications between oncology and primary care pharmacists
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Michigan Rogel Cancer Center
Solid Tumours
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate hepatic impairment compared to patients with normal hepatic function; Part B will allow…
- Trial name
- NCT01894243
- Testing
- Olaparib tablet dosing
- Where
- 12 sites in Czechia, France and 3 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02908750
- Testing
- Fexofenadine tablet dosing, Osimertininb tablet dosing
- Where
- 7 sites in France, South Korea and 1 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Solid Tumor, Hematologic Malignancy
Implementation of an Oral Chemotherapy Adherence Intervention
The goal of this study is to evaluate the effectiveness and usability of a newly developed oral anticancer agent adherence program implemented across 6 cancer clinics (two academic, two urban, and two rural).
- Trial name
- NCT06989489
- Testing
- Multilevel Adherence Intervention
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Solid Tumours
Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the pharmacokinetics (PK) of AZD9291 in patients with mild or moderate hepatic impairment compared to patients with normal hepatic function…
- Trial name
- NCT02161770
- Testing
- AZD9291 tablet dosing, Pharmacokinetic sampling - AZD9291, Pharmacokinetic sampling - AZ5140 and AZ7550
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
This is a 2-part study in patients with epidermal growth factor receptor mutation positive (EGFRm+) non-small cell lung cancer (NSCLC) whose disease has progressed on treatment with an epidermal growth factor receptor…
- Trial name
- NCT02163733
- Testing
- AZD9291 tablets, Pharmacokinetic sampling - AZD9291, Dietary Fasted
- Where
- 13 sites in France, South Korea and 2 more
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Renal Cell Carcinoma, Ovarian Carcinoma
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
The study hypothesis is that a lower starting dose of anticancer tablet treatments can lead to better treatment tolerability in older patients, while the benefits of treatment can be the same.
- Conditions
- Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma
- Trial name
- OPTI-DOSE (NCT05949424)
- Testing
- Olaparib, Lenvatinib, Sunitinib
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Cancer
Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients with Risk Factors
The rise of oral anticancer drugs favors outpatient care but exposes patients to new risks compared to injectable chemotherapy at hospital: non-adherence to treatment, inappropriate management of side effects and interactions…
- Trial name
- DROP-SFPO (NCT03257969)
- Testing
- The DROP program of pharmaceutical interventions, Standard of care
- Where
- France
- Volunteers
- 248 people
- Sponsor
- Hospices Civils de Lyon
Cancer
Optimization of the Targeted Anticancer Therapies
The study includes an observational pharmacokinetic study and an interventional medication adherence study. The purpose of this study is 1) to describe the concentration-time profiles of targeted anticancer drugs and to…
- Trial name
- OpTAT (NCT04484064)
- Testing
- Adherence program
- Where
- Switzerland
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Oral Anti-Tumor Drugs, Oral Antineoplastic Agents
Educational Intervention on Oral Anticancer Agents for Community Pharmacists
The overall aim of this study is to develop and test the feasibility and acceptability of an educational intervention for community pharmacists to provide support to patients receiving oral anticancer agents (OAAs) in the…
- Conditions
- Oral Anti-Tumor Drugs, Oral Antineoplastic Agents, Oral Anticancer Drugs
- Trial name
- NCT07677176
- Testing
- Educational intervention on managing oral anticancer agents in community pharmacy setting
- Where
- Malaysia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Monash University Malaysia
Healthy Volunteer
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
This is a Phase 1, open-label, 2-period fixed sequence design to evaluate the interaction of AZD9291 with omeprazole in approximately 50 healthy, adult male volunteers.
- Trial name
- NCT02224053
- Testing
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing
- Where
- 2 sites in United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Multidisciplinary Consultation Program, Adherence to Oral Anticancer Treatment
Impact of a Multidisciplinary Consultation Program on Drug Adherence in First Oral Anticancer Treatment
Oncology management has changed dramatically over the last decade with the approval and rapid adoption of newly targeted oral oncology medications.
- Conditions
- Multidisciplinary Consultation Program, Adherence to Oral Anticancer Treatment, Drug Related Toxicity, Securing Medication Management
- Trial name
- IMPAM (NCT04797143)
- Testing
- multidisciplinary consultation program
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Cancer, Oncology
The ROAD 2.0 to Sustainable Medication Use: Redispensing Unused Oral Anticancer Drugs
The goal of this prospective intervention study is to investigate the effectiveness of redispensing unused oral anticancer drugs.
- Conditions
- Cancer, Oncology, Pharmacy, Drug Prescriptions
- Trial name
- NCT06566560
- Testing
- redispensing oral anticancer drugs
- Where
- Netherlands
- Volunteers
- 2,500 people
- Sponsor
- Radboud University Medical Center
Oncologic Disorders
Collaborative Network to Take Responsibility for Oral Anticancer Therapy 2
In 2015, the research team of KU Leuven and UGent started a pilot project supported by Kom op Tegen Kanker, called CONTACT-1. This multicentre before-after study aims at developing, implementing and evaluating a care pathway for…
- Trial name
- CONTACT-2 (NCT04142463)
- Testing
- Care pathway
- Where
- 10 sites in Belgium
- Volunteers
- 500 people
- Sponsor
- Ilyse Kenis
Solid Tumours
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
This is a 3 part study for patients with solid tumours. The purpose of Part A is to measure the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after eating and the effect of olaparib on QT…
- Trial name
- NCT01921140
- Testing
- Olaparib tablets, Pharmacokinetic sampling, Dietary Fasted
- Where
- 12 sites in Belgium, Denmark and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Cancer, Neoplasms
Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy
New oral anticancer treatments have improved survival across cancer types but introduced challenges in medication adherence and symptom management.
- Trial name
- SMART pilot (NCT07073807)
- Testing
- SMART Intervention using TAPPT® for Adherence, Symptom, Financial, and Social Needs Monitoring
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, Irvine
Breast Cancer
Increasing Oral Medication Adherence for Metastatic Breast Cancer Patients
Aim of this study is to optimize an adherence increasing intervention designed for metastatic Breast Cancer (BC) patients by applying a full factorial design in order to evaluate the optimal combination of three different…
- Trial name
- NCT06726889
- Testing
- Standard care, Decision Support System (DSS), Reminders
- Where
- Italy
- Volunteers
- 104 people
- Sponsor
- European Institute of Oncology